Delfi Diagnostics said a cluster-randomized trial found its cfDNA-based FirstLook Lung blood test increased lung cancer screening uptake about threefold versus usual care among patients behind on recommended screening. Presented at the ATS International Conference, the company reported performance of roughly 80% sensitivity and 56% specificity with a negative predictive value of 99.8%. In nearly 3,000 patients across 28 clinics in Colorado, Florida, and North Carolina, access to the blood test increased overall screening and also boosted low-dose CT screening. Delfi said many cancers detected were stage I, supporting a potential mortality reduction pathway. Delfi reported modeling for a simulated US population of 15 million, estimating a modest (3%) increase in annual screening over five years could prevent slightly more than 3,000 deaths—driven largely by earlier-stage detection.